Basic information Safety Related Supplier
ChemicalBook >  Product Catalog >  API >  Circulatory system drugs >  Lipid regulating drugs >  Sitagliptin


Basic information Safety Related Supplier
Sitagliptin Basic information
Sitagliptin Chemical Properties
Safety Information
Sitagliptin Usage And Synthesis
  • DescriptionSitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, is a first-in-class oral drug launched for the treatment of type 2 diabetes. It acts by slowing the inactivation of incretins, which are endogenous peptides involved in the physiologic regulation of glucose homeostasis. Incretin hormones, including glucagonlike peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), are released by the intestine throughout the day, and levels are increased in response to a meal. When blood glucose concentrations are normal or elevated,GLP-1 and GIP increase the synthesis and release of insulin from pancreatic b cells via intracellular signaling pathways involving cAMP. GLP-1 also lowers glucagon secretion from pancreatic αcells, which leads to reduced hepatic glucose production.
  • OriginatorMerck (US)
  • UsesLabeled Sitagliptin , intended for use as an internal standard for the quantification of Sitagliptin by GC- or LC-mass spectrometry.
  • DefinitionChEBI: A triazolopyrazine that exhibits hypoglycemic activity.
  • brand nameJanuvia
Sitagliptin(486460-32-6)Related Product Information
  • Company Name:AnHui HaiKang Pharmaceutical Co., Ltd. Gold
  • Tel:18133004126
  • Company Name:Specpharms Scientific Research Limited Gold
  • Tel:+86 21 59971736
  • Company Name:ChemFuture PharmaTech (Jiangsu) Ltd
  • Tel:0510-85386188
  • Company Name:Chembest Research Laboratories Limited
  • Tel:021-20908456-
  • Company Name:BeiJing Hwrk Chemicals Limted
  • Tel:010-57411838 010-57411839-